<code id='DE713F44EA'></code><style id='DE713F44EA'></style>
    • <acronym id='DE713F44EA'></acronym>
      <center id='DE713F44EA'><center id='DE713F44EA'><tfoot id='DE713F44EA'></tfoot></center><abbr id='DE713F44EA'><dir id='DE713F44EA'><tfoot id='DE713F44EA'></tfoot><noframes id='DE713F44EA'>

    • <optgroup id='DE713F44EA'><strike id='DE713F44EA'><sup id='DE713F44EA'></sup></strike><code id='DE713F44EA'></code></optgroup>
        1. <b id='DE713F44EA'><label id='DE713F44EA'><select id='DE713F44EA'><dt id='DE713F44EA'><span id='DE713F44EA'></span></dt></select></label></b><u id='DE713F44EA'></u>
          <i id='DE713F44EA'><strike id='DE713F44EA'><tt id='DE713F44EA'><pre id='DE713F44EA'></pre></tt></strike></i>

          Home / knowledge / hotspot

          hotspot


          hotspot

          author:entertainment    Page View:37
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In